322 related articles for article (PubMed ID: 29756233)
21. Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics.
Guo W; Sun S; Guo L; Song P; Xue X; Zhang H; Zhang G; Li R; Gao Y; Qiu B; Tan F; Xue Q; Gao S; He J
DNA Cell Biol; 2020 Apr; 39(4):631-644. PubMed ID: 32096653
[TBL] [Abstract][Full Text] [Related]
22. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
Gupta AR; Woodard GA; Jablons DM; Mann MJ; Kratz JR
Future Oncol; 2021 Dec; 17(34):4785-4795. PubMed ID: 34435876
[TBL] [Abstract][Full Text] [Related]
23. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
24. Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer.
Huang Y; Liu Z; He L; Chen X; Pan D; Ma Z; Liang C; Tian J; Liang C
Radiology; 2016 Dec; 281(3):947-957. PubMed ID: 27347764
[TBL] [Abstract][Full Text] [Related]
25. Outcome prediction in resectable lung adenocarcinoma patients: value of CT radiomics.
Choe J; Lee SM; Do KH; Kim S; Choi S; Lee JG; Seo JB
Eur Radiol; 2020 Sep; 30(9):4952-4963. PubMed ID: 32356158
[TBL] [Abstract][Full Text] [Related]
26. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma.
Xu CH; Wang W; Wei Y; Hu HD; Zou J; Yan J; Yu LK; Yang RS; Wang Y
Eur J Surg Oncol; 2015 Oct; 41(10):1430-6. PubMed ID: 26123994
[TBL] [Abstract][Full Text] [Related]
29. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
[TBL] [Abstract][Full Text] [Related]
30. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
Yamauchi Y; Safi S; Muley T; Warth A; Herth FJF; Dienemann H; Hoffmann H; Eichhorn ME
Lung Cancer; 2017 Dec; 114():62-67. PubMed ID: 29173768
[TBL] [Abstract][Full Text] [Related]
31. A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.
Noro R; Ishigame T; Walsh N; Shiraishi K; Robles AI; Ryan BM; Schetter AJ; Bowman ED; Welsh JA; Seike M; Gemma A; Skaug V; Mollerup S; Haugen A; Yokota J; Kohno T; Harris CC
J Thorac Oncol; 2017 Jan; 12(1):65-76. PubMed ID: 27613525
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival.
Hung JJ; Yeh YC; Jeng WJ; Wu KJ; Huang BS; Wu YC; Chou TY; Hsu WH
J Clin Oncol; 2014 Aug; 32(22):2357-64. PubMed ID: 24799473
[TBL] [Abstract][Full Text] [Related]
34. Reverse engineering a predictive signature characterized by proliferation, DNA damage, and immune escape from stage I lung adenocarcinoma recurrence.
Yao J; Xue X; Qu D; Westphalen CB; Ge Y; Zhang L; Li M; Gao T; Chandrakesan P; Vega KJ; Peng J; An G; Weygant N
Acta Biochim Biophys Sin (Shanghai); 2020 Jun; 52(6):638-653. PubMed ID: 32395755
[TBL] [Abstract][Full Text] [Related]
35. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
36. Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma.
Sun Y; Hou L; Yang Y; Xie H; Yang Y; Li Z; Zhao H; Gao W; Su B
Onco Targets Ther; 2016; 9():4583-91. PubMed ID: 27524912
[TBL] [Abstract][Full Text] [Related]
37. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
38. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
40. Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma.
Cheng WC; Chang CY; Lo CC; Hsieh CY; Kuo TT; Tseng GC; Wong SC; Chiang SF; Huang KC; Lai LC; Lu TP; Chao KSC; Sher YP
Theranostics; 2021; 11(8):3661-3675. PubMed ID: 33664854
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
